New biological therapies in Sjögren's syndrome.
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by dryness and systemic involvement in more than a third of the patients. Patient management has suffered from the lack of effective treatments. However, progresses made in the understanding of pSS pathogenesis have allowed a move to a more targeted approach to therapeutic intervention. Given the key role of chronic B cell activation, B cell-targeted therapies were the first candidate. New pathways are currently investigated including costimulation and ectopic germinal centre formation. In this review, we have summarized the new tools available in clinical research in the field of pSS, the current evidence regarding B cell-targeted therapies and an overview of the promising drugs in the pipeline.
INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, Le Kremlin-Bicêtre France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. Electronic address: gaetane.nocturne@aphp.fr.
Gaetane
G
Nocturne
Department of Rheumatology, CHRU Brest, France; EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, Brest, France. Electronic address: divi.cornec@chu-brest.fr.
Divi
D
Cornec
INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, Le Kremlin-Bicêtre France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. Electronic address: raphaele.seror@aphp.fr.
Raphaèle
R
Seror
INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, Le Kremlin-Bicêtre France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France. Electronic address: xavier.mariette@aphp.fr.
Xavier
X
Mariette
D001691:Biological Therapy / Q000379:methods*; D006801:Humans; D012859:Sjogren's Syndrome / Q000276:immunology / Q000628:therapy*
B cell; Biologics; Clinical trials; Outcome measure; Primary Sjögren syndrome